#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Peripheral oxytocin and vasopressin modulates regional brain activity differently in men and women with schizophrenia Background Oxytocin (OT) and arginine vasopressin (AVP) exert sexually dimorphic effects on cognition and emotion processing.
1-1	0-10	Peripheral	_
1-2	11-19	oxytocin	_
1-3	20-23	and	_
1-4	24-35	vasopressin	_
1-5	36-45	modulates	_
1-6	46-54	regional	_
1-7	55-60	brain	_
1-8	61-69	activity	_
1-9	70-81	differently	_
1-10	82-84	in	_
1-11	85-88	men	http://maven.renci.org/NeuroBridge/neurobridge#Menopause
1-12	89-92	and	_
1-13	93-98	women	_
1-14	99-103	with	_
1-15	104-117	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-16	118-128	Background	_
1-17	129-137	Oxytocin	_
1-18	138-139	(	_
1-19	140-142	OT	_
1-20	143-144	)	_
1-21	145-148	and	_
1-22	149-157	arginine	_
1-23	158-169	vasopressin	_
1-24	170-171	(	_
1-25	172-175	AVP	_
1-26	176-177	)	_
1-27	178-183	exert	_
1-28	184-192	sexually	_
1-29	193-202	dimorphic	_
1-30	203-210	effects	_
1-31	211-213	on	_
1-32	214-223	cognition	_
1-33	224-227	and	_
1-34	228-235	emotion	_
1-35	236-246	processing	_
1-36	247-248	.	_

Text=Abnormalities in these hormones are observed in schizophrenia and may contribute to multiple established sex differences associated with the disorder.
2-1	249-262	Abnormalities	_
2-2	263-265	in	_
2-3	266-271	these	_
2-4	272-280	hormones	_
2-5	281-284	are	_
2-6	285-293	observed	_
2-7	294-296	in	_
2-8	297-310	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-9	311-314	and	_
2-10	315-318	may	_
2-11	319-329	contribute	_
2-12	330-332	to	_
2-13	333-341	multiple	_
2-14	342-353	established	_
2-15	354-357	sex	_
2-16	358-369	differences	_
2-17	370-380	associated	_
2-18	381-385	with	_
2-19	386-389	the	_
2-20	390-398	disorder	_
2-21	399-400	.	_

Text=Here we examined sex-dependent hormone associations with resting brain activity and their clinical associations in schizophrenia patients.
3-1	401-405	Here	_
3-2	406-408	we	_
3-3	409-417	examined	_
3-4	418-431	sex-dependent	_
3-5	432-439	hormone	_
3-6	440-452	associations	_
3-7	453-457	with	_
3-8	458-465	resting	_
3-9	466-471	brain	_
3-10	472-480	activity	_
3-11	481-484	and	_
3-12	485-490	their	_
3-13	491-499	clinical	_
3-14	500-512	associations	_
3-15	513-515	in	_
3-16	516-529	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-17	530-538	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-18	539-540	.	_

Text=Methods OT and AVP serum concentrations were assayed in 35 individuals with schizophrenia (23 men) and 60 controls (24 men) from the Chicago BSNIP study site.
4-1	541-548	Methods	_
4-2	549-551	OT	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-3	552-555	and	_
4-4	556-559	AVP	http://maven.renci.org/NeuroBridge/neurobridge#DiabetesInsipidus
4-5	560-565	serum	_
4-6	566-580	concentrations	_
4-7	581-585	were	_
4-8	586-593	assayed	_
4-9	594-596	in	_
4-10	597-599	35	_
4-11	600-611	individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-12	612-616	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-13	617-630	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-14	631-632	(	_
4-15	633-635	23	_
4-16	636-639	men	_
4-17	640-641	)	_
4-18	642-645	and	_
4-19	646-648	60	_
4-20	649-657	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-21	658-659	(	_
4-22	660-662	24	_
4-23	663-666	men	_
4-24	667-668	)	_
4-25	669-673	from	_
4-26	674-677	the	_
4-27	678-685	Chicago	_
4-28	686-691	BSNIP	_
4-29	692-697	study	_
4-30	698-702	site	_
4-31	703-704	.	_

Text=Regional cerebral function was assessed with resting state fMRI by measuring the amplitude of low-frequency fluctuations (ALFF) which are believed to reflect intrinsic spontaneous neuronal activity.
5-1	705-713	Regional	_
5-2	714-722	cerebral	_
5-3	723-731	function	_
5-4	732-735	was	_
5-5	736-744	assessed	_
5-6	745-749	with	_
5-7	750-757	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-8	758-763	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-9	764-768	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-10	769-771	by	_
5-11	772-781	measuring	_
5-12	782-785	the	_
5-13	786-795	amplitude	_
5-14	796-798	of	_
5-15	799-812	low-frequency	_
5-16	813-825	fluctuations	_
5-17	826-827	(	_
5-18	828-832	ALFF	_
5-19	833-834	)	_
5-20	835-840	which	_
5-21	841-844	are	_
5-22	845-853	believed	_
5-23	854-856	to	_
5-24	857-864	reflect	_
5-25	865-874	intrinsic	_
5-26	875-886	spontaneous	_
5-27	887-895	neuronal	_
5-28	896-904	activity	_
5-29	905-906	.	_

Text=Results In female patients, lower OT levels were associated with lower ALFF in frontal and cerebellar cortices (p ’ s <0.05) and in female controls AVP levels were inversely associated with ALFF in the frontal cortex (p=0.01).
6-1	907-914	Results	_
6-2	915-917	In	_
6-3	918-924	female	_
6-4	925-933	patients	_
6-5	934-935	,	_
6-6	936-941	lower	_
6-7	942-944	OT	_
6-8	945-951	levels	_
6-9	952-956	were	_
6-10	957-967	associated	_
6-11	968-972	with	_
6-12	973-978	lower	_
6-13	979-983	ALFF	_
6-14	984-986	in	_
6-15	987-994	frontal	_
6-16	995-998	and	_
6-17	999-1009	cerebellar	_
6-18	1010-1018	cortices	_
6-19	1019-1020	(	_
6-20	1021-1022	p	_
6-21	1023-1024	’	_
6-22	1025-1026	s	_
6-23	1027-1028	<	_
6-24	1029-1033	0.05	_
6-25	1034-1035	)	_
6-26	1036-1039	and	_
6-27	1040-1042	in	_
6-28	1043-1049	female	_
6-29	1050-1058	controls	_
6-30	1059-1062	AVP	http://maven.renci.org/NeuroBridge/neurobridge#DiabetesInsipidus
6-31	1063-1069	levels	_
6-32	1070-1074	were	_
6-33	1075-1084	inversely	_
6-34	1085-1095	associated	_
6-35	1096-1100	with	_
6-36	1101-1105	ALFF	_
6-37	1106-1108	in	_
6-38	1109-1112	the	_
6-39	1113-1120	frontal	_
6-40	1121-1127	cortex	_
6-41	1128-1129	(	_
6-42	1130-1136	p=0.01	_
6-43	1137-1138	)	_
6-44	1139-1140	.	_

Text=In male patients, lower OT levels were associated with lower ALFF in the posterior cingulate and lower AVP levels were associated with lower ALFF in frontal cortex (p ’ s <0.05).
7-1	1141-1143	In	_
7-2	1144-1148	male	_
7-3	1149-1157	patients	_
7-4	1158-1159	,	_
7-5	1160-1165	lower	_
7-6	1166-1168	OT	_
7-7	1169-1175	levels	_
7-8	1176-1180	were	_
7-9	1181-1191	associated	_
7-10	1192-1196	with	_
7-11	1197-1202	lower	_
7-12	1203-1207	ALFF	_
7-13	1208-1210	in	_
7-14	1211-1214	the	_
7-15	1215-1224	posterior	_
7-16	1225-1234	cingulate	_
7-17	1235-1238	and	_
7-18	1239-1244	lower	_
7-19	1245-1248	AVP	_
7-20	1249-1255	levels	_
7-21	1256-1260	were	_
7-22	1261-1271	associated	_
7-23	1272-1276	with	_
7-24	1277-1282	lower	_
7-25	1283-1287	ALFF	_
7-26	1288-1290	in	_
7-27	1291-1298	frontal	_
7-28	1299-1305	cortex	_
7-29	1306-1307	(	_
7-30	1308-1309	p	_
7-31	1310-1311	’	_
7-32	1312-1313	s	_
7-33	1314-1315	<	_
7-34	1316-1320	0.05	_
7-35	1321-1322	)	_
7-36	1323-1324	.	_

Text=In male controls, lower OT levels were associated with lower ALFF in frontal cortex and higher ALFF in the thalamus (p ’ s <0.05).
8-1	1325-1327	In	_
8-2	1328-1332	male	_
8-3	1333-1341	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
8-4	1342-1343	,	_
8-5	1344-1349	lower	_
8-6	1350-1352	OT	_
8-7	1353-1359	levels	_
8-8	1360-1364	were	_
8-9	1365-1375	associated	_
8-10	1376-1380	with	_
8-11	1381-1386	lower	_
8-12	1387-1391	ALFF	_
8-13	1392-1394	in	_
8-14	1395-1402	frontal	_
8-15	1403-1409	cortex	_
8-16	1410-1413	and	_
8-17	1414-1420	higher	_
8-18	1421-1425	ALFF	_
8-19	1426-1428	in	_
8-20	1429-1432	the	_
8-21	1433-1441	thalamus	_
8-22	1442-1443	(	_
8-23	1444-1445	p	_
8-24	1446-1447	’	_
8-25	1448-1449	s	_
8-26	1450-1451	<	_
8-27	1452-1456	0.05	_
8-28	1457-1458	)	_
8-29	1459-1460	.	_

Text=There were some inverse ALFF-behavior associations in patients.
9-1	1461-1466	There	_
9-2	1467-1471	were	_
9-3	1472-1476	some	_
9-4	1477-1484	inverse	_
9-5	1485-1498	ALFF-behavior	_
9-6	1499-1511	associations	_
9-7	1512-1514	in	_
9-8	1515-1523	patients	_
9-9	1524-1525	.	_

Text=Conclusions Alterations in peripheral hormone levels are associated with resting brain physiology in a sex-dependent manner in schizophrenia.
10-1	1526-1537	Conclusions	_
10-2	1538-1549	Alterations	_
10-3	1550-1552	in	_
10-4	1553-1563	peripheral	_
10-5	1564-1571	hormone	_
10-6	1572-1578	levels	_
10-7	1579-1582	are	_
10-8	1583-1593	associated	_
10-9	1594-1598	with	_
10-10	1599-1606	resting	_
10-11	1607-1612	brain	_
10-12	1613-1623	physiology	_
10-13	1624-1626	in	_
10-14	1627-1628	a	_
10-15	1629-1642	sex-dependent	_
10-16	1643-1649	manner	_
10-17	1650-1652	in	_
10-18	1653-1666	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-19	1667-1668	.	_

Text=These effects may contribute to sex differences in psychiatric symptom severity and course of illness in schizophrenia.
11-1	1669-1674	These	_
11-2	1675-1682	effects	_
11-3	1683-1686	may	_
11-4	1687-1697	contribute	_
11-5	1698-1700	to	_
11-6	1701-1704	sex	_
11-7	1705-1716	differences	_
11-8	1717-1719	in	_
11-9	1720-1731	psychiatric	_
11-10	1732-1739	symptom	_
11-11	1740-1748	severity	_
11-12	1749-1752	and	_
11-13	1753-1759	course	_
11-14	1760-1762	of	_
11-15	1763-1770	illness	_
11-16	1771-1773	in	_
11-17	1774-1787	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-18	1788-1789	.	_

Text=2.
12-1	1790-1791	2	_
12-2	1792-1793	.	_

Text=Methods 2.1.
13-1	1794-1801	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	1802-1805	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	1806-1807	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

Text=Participants Participants included 35 individuals with DSM-IV diagnoses of schizophrenia (12 women, 23 men) and 60 healthy individuals (36 women, 24 men) from the Chicago site of the Bipolar and Schizophrenia Network on Intermediate Phenotypes (B-SNIP) consortium at which plasma for endocrine assays was obtained.
14-1	1808-1820	Participants	_
14-2	1821-1833	Participants	_
14-3	1834-1842	included	_
14-4	1843-1845	35	_
14-5	1846-1857	individuals	_
14-6	1858-1862	with	_
14-7	1863-1869	DSM-IV	_
14-8	1870-1879	diagnoses	_
14-9	1880-1882	of	_
14-10	1883-1896	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-11	1897-1898	(	_
14-12	1899-1901	12	_
14-13	1902-1907	women	_
14-14	1908-1909	,	_
14-15	1910-1912	23	_
14-16	1913-1916	men	_
14-17	1917-1918	)	_
14-18	1919-1922	and	_
14-19	1923-1925	60	_
14-20	1926-1933	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-21	1934-1945	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-22	1946-1947	(	_
14-23	1948-1950	36	_
14-24	1951-1956	women	_
14-25	1957-1958	,	_
14-26	1959-1961	24	_
14-27	1962-1965	men	_
14-28	1966-1967	)	_
14-29	1968-1972	from	_
14-30	1973-1976	the	_
14-31	1977-1984	Chicago	_
14-32	1985-1989	site	_
14-33	1990-1992	of	_
14-34	1993-1996	the	_
14-35	1997-2004	Bipolar	_
14-36	2005-2008	and	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-37	2009-2022	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-38	2023-2030	Network	_
14-39	2031-2033	on	_
14-40	2034-2046	Intermediate	_
14-41	2047-2057	Phenotypes	_
14-42	2058-2059	(	_
14-43	2060-2066	B-SNIP	_
14-44	2067-2068	)	_
14-45	2069-2079	consortium	_
14-46	2080-2082	at	_
14-47	2083-2088	which	_
14-48	2089-2095	plasma	_
14-49	2096-2099	for	_
14-50	2100-2109	endocrine	_
14-51	2110-2116	assays	_
14-52	2117-2120	was	_
14-53	2121-2129	obtained	_
14-54	2130-2131	.	_

Text=Recruitment, diagnostic strategies and patient characteristics have been described previously (Table 1).
15-1	2132-2143	Recruitment	_
15-2	2144-2145	,	_
15-3	2146-2156	diagnostic	_
15-4	2157-2167	strategies	_
15-5	2168-2171	and	_
15-6	2172-2179	patient	_
15-7	2180-2195	characteristics	_
15-8	2196-2200	have	_
15-9	2201-2205	been	_
15-10	2206-2215	described	_
15-11	2216-2226	previously	_
15-12	2227-2228	(	_
15-13	2229-2234	Table	_
15-14	2235-2236	1	_
15-15	2237-2238	)	_
15-16	2239-2240	.	_

Text=All participants provided written informed consent and the study was approved by the University of Illinois at Chicago Institutional Review Board.
16-1	2241-2244	All	_
16-2	2245-2257	participants	_
16-3	2258-2266	provided	_
16-4	2267-2274	written	_
16-5	2275-2283	informed	_
16-6	2284-2291	consent	_
16-7	2292-2295	and	_
16-8	2296-2299	the	_
16-9	2300-2305	study	_
16-10	2306-2309	was	_
16-11	2310-2318	approved	_
16-12	2319-2321	by	_
16-13	2322-2325	the	_
16-14	2326-2336	University	_
16-15	2337-2339	of	_
16-16	2340-2348	Illinois	_
16-17	2349-2351	at	_
16-18	2352-2359	Chicago	_
16-19	2360-2373	Institutional	_
16-20	2374-2380	Review	_
16-21	2381-2386	Board	_
16-22	2387-2388	.	_

Text=A diagnosis of schizophrenia was made at consensus meetings using all available information including findings from the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID).
17-1	2389-2390	A	_
17-2	2391-2400	diagnosis	_
17-3	2401-2403	of	_
17-4	2404-2417	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-5	2418-2421	was	_
17-6	2422-2426	made	_
17-7	2427-2429	at	_
17-8	2430-2439	consensus	_
17-9	2440-2448	meetings	_
17-10	2449-2454	using	_
17-11	2455-2458	all	_
17-12	2459-2468	available	_
17-13	2469-2480	information	_
17-14	2481-2490	including	_
17-15	2491-2499	findings	_
17-16	2500-2504	from	_
17-17	2505-2508	the	_
17-18	2509-2519	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-19	2520-2528	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-20	2529-2538	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-21	2539-2542	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-22	2543-2549	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-23	2550-2554	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-24	2555-2556	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-25	2557-2566	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-26	2567-2568	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-27	2569-2573	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-28	2574-2575	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
17-29	2576-2577	.	_

Text=Healthy comparison subjects had no history of a psychotic disorder or recurrent depression, and no known immediate family history of these disorders.
18-1	2578-2585	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#Comparison
18-2	2586-2596	comparison	http://maven.renci.org/NeuroBridge/neurobridge#Comparison
18-3	2597-2605	subjects	_
18-4	2606-2609	had	_
18-5	2610-2612	no	_
18-6	2613-2620	history	_
18-7	2621-2623	of	_
18-8	2624-2625	a	_
18-9	2626-2635	psychotic	_
18-10	2636-2644	disorder	_
18-11	2645-2647	or	_
18-12	2648-2657	recurrent	_
18-13	2658-2668	depression	_
18-14	2669-2670	,	_
18-15	2671-2674	and	_
18-16	2675-2677	no	_
18-17	2678-2683	known	_
18-18	2684-2693	immediate	_
18-19	2694-2700	family	_
18-20	2701-2708	history	_
18-21	2709-2711	of	_
18-22	2712-2717	these	_
18-23	2718-2727	disorders	_
18-24	2728-2729	.	_

Text=Exclusion criteria for all participants included: history of head injury with loss of consciousness> 10 minutes; pregnancy; positive urine toxicology screen for common drugs of abuse on the day of testing; diagnosis of substance abuse in the past 30 days or substance dependence in the past 6 months; history of systemic medical or neurological disorder affecting mood or cognition; or age-corrected Wide-Range Achievement Test reading test standard score ≤70.
19-1	2730-2739	Exclusion	_
19-2	2740-2748	criteria	_
19-3	2749-2752	for	_
19-4	2753-2756	all	_
19-5	2757-2769	participants	_
19-6	2770-2778	included	_
19-7	2779-2780	:	_
19-8	2781-2788	history	_
19-9	2789-2791	of	_
19-10	2792-2796	head	_
19-11	2797-2803	injury	_
19-12	2804-2808	with	_
19-13	2809-2813	loss	_
19-14	2814-2816	of	_
19-15	2817-2830	consciousness	_
19-16	2831-2832	>	_
19-17	2833-2835	10	_
19-18	2836-2843	minutes	_
19-19	2844-2845	;	_
19-20	2846-2855	pregnancy	_
19-21	2856-2857	;	_
19-22	2858-2866	positive	_
19-23	2867-2872	urine	_
19-24	2873-2883	toxicology	_
19-25	2884-2890	screen	_
19-26	2891-2894	for	_
19-27	2895-2901	common	_
19-28	2902-2907	drugs	_
19-29	2908-2910	of	_
19-30	2911-2916	abuse	_
19-31	2917-2919	on	_
19-32	2920-2923	the	_
19-33	2924-2927	day	_
19-34	2928-2930	of	_
19-35	2931-2938	testing	_
19-36	2939-2940	;	_
19-37	2941-2950	diagnosis	_
19-38	2951-2953	of	_
19-39	2954-2963	substance	_
19-40	2964-2969	abuse	_
19-41	2970-2972	in	_
19-42	2973-2976	the	_
19-43	2977-2981	past	_
19-44	2982-2984	30	_
19-45	2985-2989	days	_
19-46	2990-2992	or	_
19-47	2993-3002	substance	_
19-48	3003-3013	dependence	_
19-49	3014-3016	in	_
19-50	3017-3020	the	_
19-51	3021-3025	past	_
19-52	3026-3027	6	_
19-53	3028-3034	months	_
19-54	3035-3036	;	_
19-55	3037-3044	history	_
19-56	3045-3047	of	_
19-57	3048-3056	systemic	_
19-58	3057-3064	medical	_
19-59	3065-3067	or	_
19-60	3068-3080	neurological	_
19-61	3081-3089	disorder	_
19-62	3090-3099	affecting	_
19-63	3100-3104	mood	_
19-64	3105-3107	or	_
19-65	3108-3117	cognition	_
19-66	3118-3119	;	_
19-67	3120-3122	or	_
19-68	3123-3136	age-corrected	_
19-69	3137-3147	Wide-Range	_
19-70	3148-3159	Achievement	_
19-71	3160-3164	Test	_
19-72	3165-3172	reading	_
19-73	3173-3177	test	_
19-74	3178-3186	standard	_
19-75	3187-3192	score	_
19-76	3193-3196	≤70	_
19-77	3197-3198	.	_

Text=2.2 Serum hormone assays Blood samples were drawn in the morning when possible (97% blood draws before noon).
20-1	3199-3202	2.2	_
20-2	3203-3208	Serum	_
20-3	3209-3216	hormone	_
20-4	3217-3223	assays	_
20-5	3224-3229	Blood	_
20-6	3230-3237	samples	_
20-7	3238-3242	were	_
20-8	3243-3248	drawn	_
20-9	3249-3251	in	_
20-10	3252-3255	the	_
20-11	3256-3263	morning	_
20-12	3264-3268	when	_
20-13	3269-3277	possible	_
20-14	3278-3279	(	_
20-15	3280-3282	97	_
20-16	3283-3284	%	_
20-17	3285-3290	blood	_
20-18	3291-3296	draws	_
20-19	3297-3303	before	_
20-20	3304-3308	noon	_
20-21	3309-3310	)	_
20-22	3311-3312	.	_

Text=Samples were stored in plain tubes, spun at 4°C, divided into aliquots (300ul), and stored at −80°C.
21-1	3313-3320	Samples	_
21-2	3321-3325	were	_
21-3	3326-3332	stored	_
21-4	3333-3335	in	_
21-5	3336-3341	plain	_
21-6	3342-3347	tubes	_
21-7	3348-3349	,	_
21-8	3350-3354	spun	_
21-9	3355-3357	at	_
21-10	3358-3361	4°C	_
21-11	3362-3363	,	_
21-12	3364-3371	divided	_
21-13	3372-3376	into	_
21-14	3377-3385	aliquots	_
21-15	3386-3387	(	_
21-16	3388-3393	300ul	_
21-17	3394-3395	)	_
21-18	3396-3397	,	_
21-19	3398-3401	and	_
21-20	3402-3408	stored	_
21-21	3409-3411	at	_
21-22	3412-3417	−80°C	_
21-23	3418-3419	.	_

Text=Samples were batched, diluted in an assay buffer to give reliable results within the linear portion of the standard curve (OT 1:4; AVP 1:2), and completed in duplicate using unextracted plasma.
22-1	3420-3427	Samples	_
22-2	3428-3432	were	_
22-3	3433-3440	batched	_
22-4	3441-3442	,	_
22-5	3443-3450	diluted	_
22-6	3451-3453	in	_
22-7	3454-3456	an	_
22-8	3457-3462	assay	_
22-9	3463-3469	buffer	_
22-10	3470-3472	to	_
22-11	3473-3477	give	_
22-12	3478-3486	reliable	_
22-13	3487-3494	results	_
22-14	3495-3501	within	_
22-15	3502-3505	the	_
22-16	3506-3512	linear	_
22-17	3513-3520	portion	_
22-18	3521-3523	of	_
22-19	3524-3527	the	_
22-20	3528-3536	standard	_
22-21	3537-3542	curve	_
22-22	3543-3544	(	_
22-23	3545-3547	OT	_
22-24	3548-3551	1:4	_
22-25	3552-3553	;	_
22-26	3554-3557	AVP	_
22-27	3558-3561	1:2	_
22-28	3562-3563	)	_
22-29	3564-3565	,	_
22-30	3566-3569	and	_
22-31	3570-3579	completed	_
22-32	3580-3582	in	_
22-33	3583-3592	duplicate	_
22-34	3593-3598	using	_
22-35	3599-3610	unextracted	_
22-36	3611-3617	plasma	_
22-37	3618-3619	.	_

Text=EIA kits (Enzo Life Sciences/Assay Designs) were used to quantify OT and AVP and both hormones were assayed simultaneously.
23-1	3620-3623	EIA	_
23-2	3624-3628	kits	_
23-3	3629-3630	(	_
23-4	3631-3635	Enzo	_
23-5	3636-3640	Life	_
23-6	3641-3655	Sciences/Assay	_
23-7	3656-3663	Designs	_
23-8	3664-3665	)	_
23-9	3666-3670	were	_
23-10	3671-3675	used	_
23-11	3676-3678	to	_
23-12	3679-3687	quantify	_
23-13	3688-3690	OT	_
23-14	3691-3694	and	_
23-15	3695-3698	AVP	_
23-16	3699-3702	and	_
23-17	3703-3707	both	_
23-18	3708-3716	hormones	_
23-19	3717-3721	were	_
23-20	3722-3729	assayed	_
23-21	3730-3744	simultaneously	_
23-22	3745-3746	.	_

Text=Samples were not extracted prior to performing the EIA as studies using mass spectrometry demonstrate high levels of OT in plasma and serum and indicate that methods involving extraction of samples removes much of this peptide.
24-1	3747-3754	Samples	_
24-2	3755-3759	were	_
24-3	3760-3763	not	_
24-4	3764-3773	extracted	_
24-5	3774-3779	prior	_
24-6	3780-3782	to	_
24-7	3783-3793	performing	_
24-8	3794-3797	the	_
24-9	3798-3801	EIA	_
24-10	3802-3804	as	_
24-11	3805-3812	studies	_
24-12	3813-3818	using	_
24-13	3819-3823	mass	_
24-14	3824-3836	spectrometry	_
24-15	3837-3848	demonstrate	_
24-16	3849-3853	high	_
24-17	3854-3860	levels	_
24-18	3861-3863	of	_
24-19	3864-3866	OT	_
24-20	3867-3869	in	_
24-21	3870-3876	plasma	_
24-22	3877-3880	and	_
24-23	3881-3886	serum	_
24-24	3887-3890	and	_
24-25	3891-3899	indicate	_
24-26	3900-3904	that	_
24-27	3905-3912	methods	_
24-28	3913-3922	involving	_
24-29	3923-3933	extraction	_
24-30	3934-3936	of	_
24-31	3937-3944	samples	_
24-32	3945-3952	removes	_
24-33	3953-3957	much	_
24-34	3958-3960	of	_
24-35	3961-3965	this	_
24-36	3966-3973	peptide	_
24-37	3974-3975	.	_

Text=These EIAs are highly sensitive (minimal detection levels <12 pg/ml OT; 4 pg/ml AVP) and cross-reactivity between OT and AVP is low (<0.04%).
25-1	3976-3981	These	_
25-2	3982-3986	EIAs	_
25-3	3987-3990	are	_
25-4	3991-3997	highly	_
25-5	3998-4007	sensitive	_
25-6	4008-4009	(	_
25-7	4010-4017	minimal	_
25-8	4018-4027	detection	_
25-9	4028-4034	levels	_
25-10	4035-4036	<	_
25-11	4037-4039	12	_
25-12	4040-4045	pg/ml	_
25-13	4046-4048	OT	_
25-14	4049-4050	;	_
25-15	4051-4052	4	_
25-16	4053-4058	pg/ml	_
25-17	4059-4062	AVP	_
25-18	4063-4064	)	_
25-19	4065-4068	and	_
25-20	4069-4085	cross-reactivity	_
25-21	4086-4093	between	_
25-22	4094-4096	OT	_
25-23	4097-4100	and	_
25-24	4101-4104	AVP	_
25-25	4105-4107	is	_
25-26	4108-4111	low	_
25-27	4112-4113	(	_
25-28	4114-4115	<	_
25-29	4116-4120	0.04	_
25-30	4121-4122	%	_
25-31	4123-4124	)	_
25-32	4125-4126	.	_

Text=All OT values> 2000 pg/ml and AVP values> 400 pg/ml were re-run to confirm sample accuracy.
26-1	4127-4130	All	_
26-2	4131-4133	OT	_
26-3	4134-4140	values	_
26-4	4141-4142	>	_
26-5	4143-4147	2000	_
26-6	4148-4153	pg/ml	_
26-7	4154-4157	and	_
26-8	4158-4161	AVP	_
26-9	4162-4168	values	_
26-10	4169-4170	>	_
26-11	4171-4174	400	_
26-12	4175-4180	pg/ml	_
26-13	4181-4185	were	_
26-14	4186-4192	re-run	_
26-15	4193-4195	to	_
26-16	4196-4203	confirm	_
26-17	4204-4210	sample	_
26-18	4211-4219	accuracy	_
26-19	4220-4221	.	_

Text=This was only the case for OT level; no cases had AVP values> 400pg/ml.
27-1	4222-4226	This	_
27-2	4227-4230	was	_
27-3	4231-4235	only	_
27-4	4236-4239	the	_
27-5	4240-4244	case	_
27-6	4245-4248	for	_
27-7	4249-4251	OT	_
27-8	4252-4257	level	_
27-9	4258-4259	;	_
27-10	4260-4262	no	_
27-11	4263-4268	cases	_
27-12	4269-4272	had	_
27-13	4273-4276	AVP	_
27-14	4277-4283	values	_
27-15	4284-4285	>	_
27-16	4286-4294	400pg/ml	_
27-17	4295-4296	.	_

Text=For both assays, intra-assay coefficients of variation were <10.7%.
28-1	4297-4300	For	_
28-2	4301-4305	both	_
28-3	4306-4312	assays	_
28-4	4313-4314	,	_
28-5	4315-4326	intra-assay	_
28-6	4327-4339	coefficients	_
28-7	4340-4342	of	_
28-8	4343-4352	variation	_
28-9	4353-4357	were	_
28-10	4358-4359	<	_
28-11	4360-4364	10.7	_
28-12	4365-4366	%	_
28-13	4367-4368	.	_

Text=Hormone values were log transformed for statistical analysis.
29-1	4369-4376	Hormone	_
29-2	4377-4383	values	_
29-3	4384-4388	were	_
29-4	4389-4392	log	_
29-5	4393-4404	transformed	_
29-6	4405-4408	for	_
29-7	4409-4420	statistical	_
29-8	4421-4429	analysis	_
29-9	4430-4431	.	_

Text=Mean daily chlorpromazine equivalent in patients was not associated with OT (r=−0.21, p=0.33) or AVP levels (r=−0.07, p=0.74).
30-1	4432-4436	Mean	_
30-2	4437-4442	daily	_
30-3	4443-4457	chlorpromazine	_
30-4	4458-4468	equivalent	_
30-5	4469-4471	in	_
30-6	4472-4480	patients	_
30-7	4481-4484	was	_
30-8	4485-4488	not	_
30-9	4489-4499	associated	_
30-10	4500-4504	with	_
30-11	4505-4507	OT	_
30-12	4508-4509	(	_
30-13	4510-4517	r=−0.21	_
30-14	4518-4519	,	_
30-15	4520-4526	p=0.33	_
30-16	4527-4528	)	_
30-17	4529-4531	or	_
30-18	4532-4535	AVP	_
30-19	4536-4542	levels	_
30-20	4543-4544	(	_
30-21	4545-4552	r=−0.07	_
30-22	4553-4554	,	_
30-23	4555-4561	p=0.74	_
30-24	4562-4563	)	_
30-25	4564-4565	.	_

Text=Age was associated with OT (r=0.23, p=0.03), but not AVP levels (r=0.13, p=0.23).
31-1	4566-4569	Age	_
31-2	4570-4573	was	_
31-3	4574-4584	associated	_
31-4	4585-4589	with	_
31-5	4590-4592	OT	_
31-6	4593-4594	(	_
31-7	4595-4601	r=0.23	_
31-8	4602-4603	,	_
31-9	4604-4610	p=0.03	_
31-10	4611-4612	)	_
31-11	4613-4614	,	_
31-12	4615-4618	but	_
31-13	4619-4622	not	_
31-14	4623-4626	AVP	http://maven.renci.org/NeuroBridge/neurobridge#DiabetesInsipidus
31-15	4627-4633	levels	_
31-16	4634-4635	(	_
31-17	4636-4642	r=0.13	_
31-18	4643-4644	,	_
31-19	4645-4651	p=0.23	_
31-20	4652-4653	)	_
31-21	4654-4655	.	_

Text=2.3.
32-1	4656-4659	2.3	_
32-2	4660-4661	.	_

Text=Emotion processing and cognition From the Brief Assessment of Cognition in Schizophrenia (BACS) neuropsychological test battery, we selected three subtests including verbal learning (list learning), verbal fluency (word generation), and processing speed (symbol-coding).
33-1	4662-4669	Emotion	_
33-2	4670-4680	processing	_
33-3	4681-4684	and	_
33-4	4685-4694	cognition	_
33-5	4695-4699	From	_
33-6	4700-4703	the	_
33-7	4704-4709	Brief	_
33-8	4710-4720	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
33-9	4721-4723	of	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
33-10	4724-4733	Cognition	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
33-11	4734-4736	in	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
33-12	4737-4750	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
33-13	4751-4752	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
33-14	4753-4757	BACS	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
33-15	4758-4759	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefAssessmentofCognitioninSchizophrenia
33-16	4760-4778	neuropsychological	_
33-17	4779-4783	test	_
33-18	4784-4791	battery	_
33-19	4792-4793	,	_
33-20	4794-4796	we	_
33-21	4797-4805	selected	_
33-22	4806-4811	three	_
33-23	4812-4820	subtests	_
33-24	4821-4830	including	_
33-25	4831-4837	verbal	_
33-26	4838-4846	learning	_
33-27	4847-4848	(	_
33-28	4849-4853	list	_
33-29	4854-4862	learning	_
33-30	4863-4864	)	_
33-31	4865-4866	,	_
33-32	4867-4873	verbal	_
33-33	4874-4881	fluency	_
33-34	4882-4883	(	_
33-35	4884-4888	word	_
33-36	4889-4899	generation	_
33-37	4900-4901	)	_
33-38	4902-4903	,	_
33-39	4904-4907	and	_
33-40	4908-4918	processing	_
33-41	4919-4924	speed	_
33-42	4925-4926	(	_
33-43	4927-4940	symbol-coding	_
33-44	4941-4942	)	_
33-45	4943-4944	.	_

Text=The Penn Emotion Recognition (ER) -40 Test assessed the ability to accurately recognize facial emotions.
34-1	4945-4948	The	_
34-2	4949-4953	Penn	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
34-3	4954-4961	Emotion	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
34-4	4962-4973	Recognition	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
34-5	4974-4975	(	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
34-6	4976-4978	ER	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
34-7	4979-4980	)	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
34-8	4981-4984	-40	_
34-9	4985-4989	Test	_
34-10	4990-4998	assessed	_
34-11	4999-5002	the	_
34-12	5003-5010	ability	_
34-13	5011-5013	to	_
34-14	5014-5024	accurately	_
34-15	5025-5034	recognize	_
34-16	5035-5041	facial	_
34-17	5042-5050	emotions	_
34-18	5051-5052	.	_

Text=These tests were selected based on previous research indicating that the tests demonstrate sex differences in the general population or if tests (verbal learning, processing speed) showed a sex difference in favor of women (p ’ s <0.01) in the large sample of healthy controls from the Bipolar and Schizophrenia Network on Intermediate Phenotypes study (N=304, 55% women).
35-1	5053-5058	These	_
35-2	5059-5064	tests	_
35-3	5065-5069	were	_
35-4	5070-5078	selected	_
35-5	5079-5084	based	_
35-6	5085-5087	on	_
35-7	5088-5096	previous	_
35-8	5097-5105	research	_
35-9	5106-5116	indicating	_
35-10	5117-5121	that	_
35-11	5122-5125	the	_
35-12	5126-5131	tests	_
35-13	5132-5143	demonstrate	_
35-14	5144-5147	sex	_
35-15	5148-5159	differences	_
35-16	5160-5162	in	_
35-17	5163-5166	the	_
35-18	5167-5174	general	_
35-19	5175-5185	population	_
35-20	5186-5188	or	_
35-21	5189-5191	if	_
35-22	5192-5197	tests	_
35-23	5198-5199	(	_
35-24	5200-5206	verbal	_
35-25	5207-5215	learning	_
35-26	5216-5217	,	_
35-27	5218-5228	processing	_
35-28	5229-5234	speed	_
35-29	5235-5236	)	_
35-30	5237-5243	showed	_
35-31	5244-5245	a	_
35-32	5246-5249	sex	_
35-33	5250-5260	difference	_
35-34	5261-5263	in	_
35-35	5264-5269	favor	_
35-36	5270-5272	of	_
35-37	5273-5278	women	_
35-38	5279-5280	(	_
35-39	5281-5282	p	_
35-40	5283-5284	’	_
35-41	5285-5286	s	_
35-42	5287-5288	<	_
35-43	5289-5293	0.01	_
35-44	5294-5295	)	_
35-45	5296-5298	in	_
35-46	5299-5302	the	_
35-47	5303-5308	large	_
35-48	5309-5315	sample	_
35-49	5316-5318	of	_
35-50	5319-5326	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
35-51	5327-5335	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
35-52	5336-5340	from	_
35-53	5341-5344	the	_
35-54	5345-5352	Bipolar	_
35-55	5353-5356	and	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
35-56	5357-5370	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
35-57	5371-5378	Network	_
35-58	5379-5381	on	_
35-59	5382-5394	Intermediate	_
35-60	5395-5405	Phenotypes	_
35-61	5406-5411	study	_
35-62	5412-5413	(	_
35-63	5414-5419	N=304	_
35-64	5420-5421	,	_
35-65	5422-5424	55	_
35-66	5425-5426	%	_
35-67	5427-5432	women	_
35-68	5433-5434	)	_
35-69	5435-5436	.	_

Text=2.4.
36-1	5437-5440	2.4	_
36-2	5441-5442	.	_

Text=Resting State Data Acquisition Participants underwent 5 minutes of scanning using a GE Signa EXCITE 3.0 Tesla MR imaging system and an 8-channel phased array head coil.
37-1	5443-5450	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-2	5451-5456	State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-3	5457-5461	Data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-4	5462-5473	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
37-5	5474-5486	Participants	_
37-6	5487-5496	underwent	_
37-7	5497-5498	5	_
37-8	5499-5506	minutes	_
37-9	5507-5509	of	_
37-10	5510-5518	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
37-11	5519-5524	using	_
37-12	5525-5526	a	_
37-13	5527-5529	GE	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-14	5530-5535	Signa	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-15	5536-5542	EXCITE	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-16	5543-5546	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-17	5547-5552	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-18	5553-5555	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-19	5556-5563	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-20	5564-5570	system	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-21	5571-5574	and	_
37-22	5575-5577	an	_
37-23	5578-5587	8-channel	_
37-24	5588-5594	phased	_
37-25	5595-5600	array	_
37-26	5601-5605	head	_
37-27	5606-5610	coil	_
37-28	5611-5612	.	_

Text=Participants fixated on a central crosshair for the duration of the scan.
38-1	5613-5625	Participants	_
38-2	5626-5633	fixated	_
38-3	5634-5636	on	_
38-4	5637-5638	a	_
38-5	5639-5646	central	_
38-6	5647-5656	crosshair	_
38-7	5657-5660	for	_
38-8	5661-5664	the	_
38-9	5665-5673	duration	_
38-10	5674-5676	of	_
38-11	5677-5680	the	_
38-12	5681-5685	scan	_
38-13	5686-5687	.	_

Text=Video monitoring of participants eyes confirmed adherence to this instruction.
39-1	5688-5693	Video	_
39-2	5694-5704	monitoring	_
39-3	5705-5707	of	_
39-4	5708-5720	participants	_
39-5	5721-5725	eyes	_
39-6	5726-5735	confirmed	_
39-7	5736-5745	adherence	_
39-8	5746-5748	to	_
39-9	5749-5753	this	_
39-10	5754-5765	instruction	_
39-11	5766-5767	.	_

Text=Soft ear plugs were used to reduce scan noise, and head motion was minimized with head cushions.
40-1	5768-5772	Soft	_
40-2	5773-5776	ear	_
40-3	5777-5782	plugs	_
40-4	5783-5787	were	_
40-5	5788-5792	used	_
40-6	5793-5795	to	_
40-7	5796-5802	reduce	_
40-8	5803-5807	scan	_
40-9	5808-5813	noise	_
40-10	5814-5815	,	_
40-11	5816-5819	and	_
40-12	5820-5824	head	_
40-13	5825-5831	motion	_
40-14	5832-5835	was	_
40-15	5836-5845	minimized	_
40-16	5846-5850	with	_
40-17	5851-5855	head	_
40-18	5856-5864	cushions	_
40-19	5865-5866	.	_

Text=Echo-planar imaging sensitive to changes in BOLD signals (repetition time= 1775msec, echo time= 27msec, flip angle= 60°) were obtained.
41-1	5867-5878	Echo-planar	_
41-2	5879-5886	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
41-3	5887-5896	sensitive	_
41-4	5897-5899	to	_
41-5	5900-5907	changes	_
41-6	5908-5910	in	_
41-7	5911-5915	BOLD	_
41-8	5916-5923	signals	_
41-9	5924-5925	(	_
41-10	5926-5936	repetition	_
41-11	5937-5942	time=	_
41-12	5943-5951	1775msec	_
41-13	5952-5953	,	_
41-14	5954-5958	echo	_
41-15	5959-5964	time=	_
41-16	5965-5971	27msec	_
41-17	5972-5973	,	_
41-18	5974-5978	flip	_
41-19	5979-5985	angle=	_
41-20	5986-5989	60°	_
41-21	5990-5991	)	_
41-22	5992-5996	were	_
41-23	5997-6005	obtained	_
41-24	6006-6007	.	_

Text=The slice thickness was 4 mm (1mm gap) with a matrix size of 64×64 and a field of view of 220×220 mm2, resulting in a voxel size of 3.44×3.44×5 mm3.
42-1	6008-6011	The	_
42-2	6012-6017	slice	_
42-3	6018-6027	thickness	_
42-4	6028-6031	was	_
42-5	6032-6033	4	_
42-6	6034-6036	mm	_
42-7	6037-6038	(	_
42-8	6039-6042	1mm	_
42-9	6043-6046	gap	_
42-10	6047-6048	)	_
42-11	6049-6053	with	_
42-12	6054-6055	a	_
42-13	6056-6062	matrix	_
42-14	6063-6067	size	_
42-15	6068-6070	of	_
42-16	6071-6076	64×64	_
42-17	6077-6080	and	_
42-18	6081-6082	a	_
42-19	6083-6088	field	_
42-20	6089-6091	of	_
42-21	6092-6096	view	_
42-22	6097-6099	of	_
42-23	6100-6107	220×220	_
42-24	6108-6111	mm2	_
42-25	6112-6113	,	_
42-26	6114-6123	resulting	_
42-27	6124-6126	in	_
42-28	6127-6128	a	_
42-29	6129-6134	voxel	_
42-30	6135-6139	size	_
42-31	6140-6142	of	_
42-32	6143-6154	3.44×3.44×5	_
42-33	6155-6158	mm3	_
42-34	6159-6160	.	_

Text=Each brain volume was comprised of 29 axial slices, and each functional run contained 210 image volumes.
43-1	6161-6165	Each	_
43-2	6166-6171	brain	_
43-3	6172-6178	volume	_
43-4	6179-6182	was	_
43-5	6183-6192	comprised	_
43-6	6193-6195	of	_
43-7	6196-6198	29	_
43-8	6199-6204	axial	_
43-9	6205-6211	slices	_
43-10	6212-6213	,	_
43-11	6214-6217	and	_
43-12	6218-6222	each	_
43-13	6223-6233	functional	_
43-14	6234-6237	run	_
43-15	6238-6247	contained	_
43-16	6248-6251	210	_
43-17	6252-6257	image	_
43-18	6258-6265	volumes	_
43-19	6266-6267	.	_

Text=2.5.
44-1	6268-6271	2.5	_
44-2	6272-6273	.	_

Text=Data Processing The first 5 volumes were discarded to achieve steady-state longitudinal magnetization.
45-1	6274-6278	Data	_
45-2	6279-6289	Processing	_
45-3	6290-6293	The	_
45-4	6294-6299	first	_
45-5	6300-6301	5	_
45-6	6302-6309	volumes	_
45-7	6310-6314	were	_
45-8	6315-6324	discarded	_
45-9	6325-6327	to	_
45-10	6328-6335	achieve	_
45-11	6336-6348	steady-state	_
45-12	6349-6361	longitudinal	_
45-13	6362-6375	magnetization	_
45-14	6376-6377	.	_

Text=Remaining data were preprocessed by Data Processing Assistant for Resting-State fMRI, version 2.3 (http: //rfmri.org/DPARSF) software, implemented within the MATLAB toolbox, including slice timing and head motion correction, spatial normalization, and smoothing with a Gaussian kernel of 6 mm3 full width at half maximum.
46-1	6378-6387	Remaining	_
46-2	6388-6392	data	_
46-3	6393-6397	were	_
46-4	6398-6410	preprocessed	_
46-5	6411-6413	by	_
46-6	6414-6418	Data	_
46-7	6419-6429	Processing	_
46-8	6430-6439	Assistant	_
46-9	6440-6443	for	_
46-10	6444-6457	Resting-State	_
46-11	6458-6462	fMRI	_
46-12	6463-6464	,	_
46-13	6465-6472	version	_
46-14	6473-6476	2.3	_
46-15	6477-6478	(	_
46-16	6479-6483	http	_
46-17	6484-6485	:	_
46-18	6486-6504	//rfmri.org/DPARSF	_
46-19	6505-6506	)	_
46-20	6507-6515	software	_
46-21	6516-6517	,	_
46-22	6518-6529	implemented	_
46-23	6530-6536	within	_
46-24	6537-6540	the	_
46-25	6541-6547	MATLAB	_
46-26	6548-6555	toolbox	_
46-27	6556-6557	,	_
46-28	6558-6567	including	_
46-29	6568-6573	slice	_
46-30	6574-6580	timing	_
46-31	6581-6584	and	_
46-32	6585-6589	head	_
46-33	6590-6596	motion	_
46-34	6597-6607	correction	_
46-35	6608-6609	,	_
46-36	6610-6617	spatial	_
46-37	6618-6631	normalization	_
46-38	6632-6633	,	_
46-39	6634-6637	and	_
46-40	6638-6647	smoothing	_
46-41	6648-6652	with	_
46-42	6653-6654	a	_
46-43	6655-6663	Gaussian	_
46-44	6664-6670	kernel	_
46-45	6671-6673	of	_
46-46	6674-6675	6	_
46-47	6676-6679	mm3	_
46-48	6680-6684	full	_
46-49	6685-6690	width	_
46-50	6691-6693	at	_
46-51	6694-6698	half	_
46-52	6699-6706	maximum	_
46-53	6707-6708	.	_

Text=fMRI images were spatially normalized to Montreal Neurological Institute space using the standard echo-planar imaging template after resampling the images to achieve a voxel resolution of 3×3×3 mm.
47-1	6709-6713	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
47-2	6714-6720	images	_
47-3	6721-6725	were	_
47-4	6726-6735	spatially	_
47-5	6736-6746	normalized	_
47-6	6747-6749	to	_
47-7	6750-6758	Montreal	_
47-8	6759-6771	Neurological	_
47-9	6772-6781	Institute	_
47-10	6782-6787	space	_
47-11	6788-6793	using	_
47-12	6794-6797	the	_
47-13	6798-6806	standard	_
47-14	6807-6818	echo-planar	_
47-15	6819-6826	imaging	_
47-16	6827-6835	template	_
47-17	6836-6841	after	_
47-18	6842-6852	resampling	_
47-19	6853-6856	the	_
47-20	6857-6863	images	_
47-21	6864-6866	to	_
47-22	6867-6874	achieve	_
47-23	6875-6876	a	_
47-24	6877-6882	voxel	_
47-25	6883-6893	resolution	_
47-26	6894-6896	of	_
47-27	6897-6902	3×3×3	_
47-28	6903-6905	mm	_
47-29	6906-6907	.	_

Text=The measurement of ALFF ranged from 0.01 to 0.08 Hz, which is believed to reflect regional spontaneous neural activity.
48-1	6908-6911	The	_
48-2	6912-6923	measurement	_
48-3	6924-6926	of	_
48-4	6927-6931	ALFF	_
48-5	6932-6938	ranged	_
48-6	6939-6943	from	_
48-7	6944-6948	0.01	_
48-8	6949-6951	to	_
48-9	6952-6956	0.08	_
48-10	6957-6959	Hz	_
48-11	6960-6961	,	_
48-12	6962-6967	which	_
48-13	6968-6970	is	_
48-14	6971-6979	believed	_
48-15	6980-6982	to	_
48-16	6983-6990	reflect	_
48-17	6991-6999	regional	_
48-18	7000-7011	spontaneous	_
48-19	7012-7018	neural	_
48-20	7019-7027	activity	_
48-21	7028-7029	.	_

Text=To achieve this, we set the bandpass filtering range as 0.01–0.08 HZ and removed the linear trend.
49-1	7030-7032	To	_
49-2	7033-7040	achieve	_
49-3	7041-7045	this	_
49-4	7046-7047	,	_
49-5	7048-7050	we	_
49-6	7051-7054	set	_
49-7	7055-7058	the	_
49-8	7059-7067	bandpass	_
49-9	7068-7077	filtering	_
49-10	7078-7083	range	_
49-11	7084-7086	as	_
49-12	7087-7096	0.01–0.08	_
49-13	7097-7099	HZ	_
49-14	7100-7103	and	_
49-15	7104-7111	removed	_
49-16	7112-7115	the	_
49-17	7116-7122	linear	_
49-18	7123-7128	trend	_
49-19	7129-7130	.	_

Text=Then, using fast Fourier transformation (parameters: taper percentage=0, fast Fourier transform length =shortest), we transformed the time series to the frequency domain, and obtained the power spectrum.
50-1	7131-7135	Then	_
50-2	7136-7137	,	_
50-3	7138-7143	using	_
50-4	7144-7148	fast	_
50-5	7149-7156	Fourier	_
50-6	7157-7171	transformation	_
50-7	7172-7173	(	_
50-8	7174-7184	parameters	_
50-9	7185-7186	:	_
50-10	7187-7192	taper	_
50-11	7193-7205	percentage=0	_
50-12	7206-7207	,	_
50-13	7208-7212	fast	_
50-14	7213-7220	Fourier	_
50-15	7221-7230	transform	_
50-16	7231-7237	length	_
50-17	7238-7247	=shortest	_
50-18	7248-7249	)	_
50-19	7250-7251	,	_
50-20	7252-7254	we	_
50-21	7255-7266	transformed	_
50-22	7267-7270	the	_
50-23	7271-7275	time	_
50-24	7276-7282	series	_
50-25	7283-7285	to	_
50-26	7286-7289	the	_
50-27	7290-7299	frequency	_
50-28	7300-7306	domain	_
50-29	7307-7308	,	_
50-30	7309-7312	and	_
50-31	7313-7321	obtained	_
50-32	7322-7325	the	_
50-33	7326-7331	power	_
50-34	7332-7340	spectrum	_
50-35	7341-7342	.	_

Text=Next, power was square root transformed and then averaged across 0.01–0.08 Hz to yield a measure of the ALFF from each voxel.
51-1	7343-7347	Next	_
51-2	7348-7349	,	_
51-3	7350-7355	power	_
51-4	7356-7359	was	_
51-5	7360-7366	square	_
51-6	7367-7371	root	_
51-7	7372-7383	transformed	_
51-8	7384-7387	and	_
51-9	7388-7392	then	_
51-10	7393-7401	averaged	_
51-11	7402-7408	across	_
51-12	7409-7418	0.01–0.08	_
51-13	7419-7421	Hz	_
51-14	7422-7424	to	_
51-15	7425-7430	yield	_
51-16	7431-7432	a	_
51-17	7433-7440	measure	_
51-18	7441-7443	of	_
51-19	7444-7447	the	_
51-20	7448-7452	ALFF	_
51-21	7453-7457	from	_
51-22	7458-7462	each	_
51-23	7463-7468	voxel	_
51-24	7469-7470	.	_

Text=Finally, the ALFF of each voxel was then divided by the global mean ALFF value of the individual to standardize data across subjects.
52-1	7471-7478	Finally	_
52-2	7479-7480	,	_
52-3	7481-7484	the	_
52-4	7485-7489	ALFF	_
52-5	7490-7492	of	_
52-6	7493-7497	each	_
52-7	7498-7503	voxel	_
52-8	7504-7507	was	_
52-9	7508-7512	then	_
52-10	7513-7520	divided	_
52-11	7521-7523	by	_
52-12	7524-7527	the	_
52-13	7528-7534	global	_
52-14	7535-7539	mean	_
52-15	7540-7544	ALFF	_
52-16	7545-7550	value	_
52-17	7551-7553	of	_
52-18	7554-7557	the	_
52-19	7558-7568	individual	_
52-20	7569-7571	to	_
52-21	7572-7583	standardize	_
52-22	7584-7588	data	_
52-23	7589-7595	across	_
52-24	7596-7604	subjects	_
52-25	7605-7606	.	_

Text=2.6.
53-1	7607-7610	2.6	_
53-2	7611-7612	.	_

Text=Statistical Analyses All statistical analytic processes were performed in REST software (Resting-State fMRI Data Analysis Toolkit V1.8; http: //restfmri.net/forum/rest).
54-1	7613-7624	Statistical	_
54-2	7625-7633	Analyses	_
54-3	7634-7637	All	_
54-4	7638-7649	statistical	_
54-5	7650-7658	analytic	_
54-6	7659-7668	processes	_
54-7	7669-7673	were	_
54-8	7674-7683	performed	_
54-9	7684-7686	in	_
54-10	7687-7691	REST	_
54-11	7692-7700	software	_
54-12	7701-7702	(	_
54-13	7703-7716	Resting-State	_
54-14	7717-7721	fMRI	_
54-15	7722-7726	Data	_
54-16	7727-7735	Analysis	_
54-17	7736-7743	Toolkit	_
54-18	7744-7748	V1.8	_
54-19	7749-7750	;	_
54-20	7751-7755	http	_
54-21	7756-7757	:	_
54-22	7758-7783	//restfmri.net/forum/rest	_
54-23	7784-7785	)	_
54-24	7786-7787	.	_

Text=First, we calculated the voxel-wise correlations between ALFF and hormone data within the patient and control groups respectively, and within male and female participants in each group, with age treated as a covariate.
55-1	7788-7793	First	_
55-2	7794-7795	,	_
55-3	7796-7798	we	_
55-4	7799-7809	calculated	_
55-5	7810-7813	the	_
55-6	7814-7824	voxel-wise	_
55-7	7825-7837	correlations	_
55-8	7838-7845	between	_
55-9	7846-7850	ALFF	_
55-10	7851-7854	and	_
55-11	7855-7862	hormone	_
55-12	7863-7867	data	_
55-13	7868-7874	within	_
55-14	7875-7878	the	_
55-15	7879-7886	patient	_
55-16	7887-7890	and	_
55-17	7891-7898	control	_
55-18	7899-7905	groups	_
55-19	7906-7918	respectively	_
55-20	7919-7920	,	_
55-21	7921-7924	and	_
55-22	7925-7931	within	_
55-23	7932-7936	male	_
55-24	7937-7940	and	_
55-25	7941-7947	female	_
55-26	7948-7960	participants	_
55-27	7961-7963	in	_
55-28	7964-7968	each	_
55-29	7969-7974	group	_
55-30	7975-7976	,	_
55-31	7977-7981	with	_
55-32	7982-7985	age	_
55-33	7986-7993	treated	_
55-34	7994-7996	as	_
55-35	7997-7998	a	_
55-36	7999-8008	covariate	_
55-37	8009-8010	.	_

Text=To detect differences in hormone-brain activity correlations between groups, voxel-based comparison of correlation maps was performed in SPM8 (http: //www.fil.ion.ecl.ac.uk/spm).
56-1	8011-8013	To	_
56-2	8014-8020	detect	_
56-3	8021-8032	differences	_
56-4	8033-8035	in	_
56-5	8036-8049	hormone-brain	_
56-6	8050-8058	activity	_
56-7	8059-8071	correlations	_
56-8	8072-8079	between	_
56-9	8080-8086	groups	_
56-10	8087-8088	,	_
56-11	8089-8100	voxel-based	_
56-12	8101-8111	comparison	_
56-13	8112-8114	of	_
56-14	8115-8126	correlation	_
56-15	8127-8131	maps	_
56-16	8132-8135	was	_
56-17	8136-8145	performed	_
56-18	8146-8148	in	_
56-19	8149-8153	SPM8	_
56-20	8154-8155	(	_
56-21	8156-8160	http	_
56-22	8161-8162	:	_
56-23	8163-8190	//www.fil.ion.ecl.ac.uk/spm	_
56-24	8191-8192	)	_
56-25	8193-8194	.	_

Text=Primary analyses compared male patients and controls, and female patients and controls.
57-1	8195-8202	Primary	_
57-2	8203-8211	analyses	_
57-3	8212-8220	compared	_
57-4	8221-8225	male	_
57-5	8226-8234	patients	_
57-6	8235-8238	and	_
57-7	8239-8247	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
57-8	8248-8249	,	_
57-9	8250-8253	and	_
57-10	8254-8260	female	_
57-11	8261-8269	patients	_
57-12	8270-8273	and	_
57-13	8274-8282	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
57-14	8283-8284	.	_

Text=The average correlation coefficient of brain regions (clusters of voxels) showing significant differences in hormone – brain physiology correlations were extracted, compared across groups, and correlated with clinical and demographic characteristics using cocor software (comparing correlations; http: //comparingcorrelations.org).
58-1	8285-8288	The	_
58-2	8289-8296	average	_
58-3	8297-8308	correlation	_
58-4	8309-8320	coefficient	_
58-5	8321-8323	of	_
58-6	8324-8329	brain	_
58-7	8330-8337	regions	_
58-8	8338-8339	(	_
58-9	8340-8348	clusters	_
58-10	8349-8351	of	_
58-11	8352-8358	voxels	_
58-12	8359-8360	)	_
58-13	8361-8368	showing	_
58-14	8369-8380	significant	_
58-15	8381-8392	differences	_
58-16	8393-8395	in	_
58-17	8396-8403	hormone	_
58-18	8404-8405	–	_
58-19	8406-8411	brain	_
58-20	8412-8422	physiology	_
58-21	8423-8435	correlations	_
58-22	8436-8440	were	_
58-23	8441-8450	extracted	_
58-24	8451-8452	,	_
58-25	8453-8461	compared	_
58-26	8462-8468	across	_
58-27	8469-8475	groups	_
58-28	8476-8477	,	_
58-29	8478-8481	and	_
58-30	8482-8492	correlated	_
58-31	8493-8497	with	_
58-32	8498-8506	clinical	_
58-33	8507-8510	and	_
58-34	8511-8522	demographic	_
58-35	8523-8538	characteristics	_
58-36	8539-8544	using	_
58-37	8545-8550	cocor	_
58-38	8551-8559	software	_
58-39	8560-8561	(	_
58-40	8562-8571	comparing	_
58-41	8572-8584	correlations	_
58-42	8585-8586	;	_
58-43	8587-8591	http	_
58-44	8592-8593	:	_
58-45	8594-8621	//comparingcorrelations.org	_
58-46	8622-8623	)	_
58-47	8624-8625	.	_

Text=Primary correlational analyses investigated relations between hormones and brain physiology, and between brain physiology and behavior.
59-1	8626-8633	Primary	_
59-2	8634-8647	correlational	_
59-3	8648-8656	analyses	_
59-4	8657-8669	investigated	_
59-5	8670-8679	relations	_
59-6	8680-8687	between	_
59-7	8688-8696	hormones	_
59-8	8697-8700	and	_
59-9	8701-8706	brain	_
59-10	8707-8717	physiology	_
59-11	8718-8719	,	_
59-12	8720-8723	and	_
59-13	8724-8731	between	_
59-14	8732-8737	brain	_
59-15	8738-8748	physiology	_
59-16	8749-8752	and	_
59-17	8753-8761	behavior	_
59-18	8762-8763	.	_

Text=A series of multivariable linear regressions were then conducted to determine whether brain physiology mediated hormone-behavior associations.
60-1	8764-8765	A	_
60-2	8766-8772	series	_
60-3	8773-8775	of	_
60-4	8776-8789	multivariable	_
60-5	8790-8796	linear	_
60-6	8797-8808	regressions	_
60-7	8809-8813	were	_
60-8	8814-8818	then	_
60-9	8819-8828	conducted	_
60-10	8829-8831	to	_
60-11	8832-8841	determine	_
60-12	8842-8849	whether	_
60-13	8850-8855	brain	_
60-14	8856-8866	physiology	_
60-15	8867-8875	mediated	_
60-16	8876-8892	hormone-behavior	_
60-17	8893-8905	associations	_
60-18	8906-8907	.	_

Text=In all image analyses, we used Monte Carlo simulations and AlphSim software to correct for multiple comparisons when testing for statistical significance.
61-1	8908-8910	In	_
61-2	8911-8914	all	_
61-3	8915-8920	image	_
61-4	8921-8929	analyses	_
61-5	8930-8931	,	_
61-6	8932-8934	we	_
61-7	8935-8939	used	_
61-8	8940-8945	Monte	_
61-9	8946-8951	Carlo	_
61-10	8952-8963	simulations	_
61-11	8964-8967	and	_
61-12	8968-8975	AlphSim	_
61-13	8976-8984	software	_
61-14	8985-8987	to	_
61-15	8988-8995	correct	_
61-16	8996-8999	for	_
61-17	9000-9008	multiple	_
61-18	9009-9020	comparisons	_
61-19	9021-9025	when	_
61-20	9026-9033	testing	_
61-21	9034-9037	for	_
61-22	9038-9049	statistical	_
61-23	9050-9062	significance	_
61-24	9063-9064	.	_

Text=The probability of a false-positive detection for the study was set to p <0.05 using a minimum cluster size of 5 contiguous voxels significant individually at a threshold of p <0.05 (http: //afni.nimh.nih.gov/pub/dist/doc/manual/AlphaSim.pdf).
62-1	9065-9068	The	_
62-2	9069-9080	probability	_
62-3	9081-9083	of	_
62-4	9084-9085	a	_
62-5	9086-9100	false-positive	_
62-6	9101-9110	detection	_
62-7	9111-9114	for	_
62-8	9115-9118	the	_
62-9	9119-9124	study	_
62-10	9125-9128	was	_
62-11	9129-9132	set	_
62-12	9133-9135	to	_
62-13	9136-9137	p	_
62-14	9138-9139	<	_
62-15	9140-9144	0.05	_
62-16	9145-9150	using	_
62-17	9151-9152	a	_
62-18	9153-9160	minimum	_
62-19	9161-9168	cluster	_
62-20	9169-9173	size	_
62-21	9174-9176	of	_
62-22	9177-9178	5	_
62-23	9179-9189	contiguous	_
62-24	9190-9196	voxels	_
62-25	9197-9208	significant	_
62-26	9209-9221	individually	_
62-27	9222-9224	at	_
62-28	9225-9226	a	_
62-29	9227-9236	threshold	_
62-30	9237-9239	of	_
62-31	9240-9241	p	_
62-32	9242-9243	<	_
62-33	9244-9248	0.05	_
62-34	9249-9250	(	_
62-35	9251-9255	http	_
62-36	9256-9257	:	_
62-37	9258-9310	//afni.nimh.nih.gov/pub/dist/doc/manual/AlphaSim.pdf	_
62-38	9311-9312	)	_
62-39	9313-9314	.	_

Text=The AlphSim calculation was conducted using REST software (http: //restfmri.net/forum/index.php), which integrated the true smoothness kernel estimated based on the statistical map and mask file.
63-1	9315-9318	The	_
63-2	9319-9326	AlphSim	_
63-3	9327-9338	calculation	_
63-4	9339-9342	was	_
63-5	9343-9352	conducted	_
63-6	9353-9358	using	_
63-7	9359-9363	REST	_
63-8	9364-9372	software	_
63-9	9373-9374	(	_
63-10	9375-9379	http	_
63-11	9380-9381	:	_
63-12	9382-9412	//restfmri.net/forum/index.php	_
63-13	9413-9414	)	_
63-14	9415-9416	,	_
63-15	9417-9422	which	_
63-16	9423-9433	integrated	_
63-17	9434-9437	the	_
63-18	9438-9442	true	_
63-19	9443-9453	smoothness	_
63-20	9454-9460	kernel	_
63-21	9461-9470	estimated	_
63-22	9471-9476	based	_
63-23	9477-9479	on	_
63-24	9480-9483	the	_
63-25	9484-9495	statistical	_
63-26	9496-9499	map	_
63-27	9500-9503	and	_
63-28	9504-9508	mask	_
63-29	9509-9513	file	_
63-30	9514-9515	.	_

